Non-Clinical Trials Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Non-Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies), By Test (In silico, In vitro, In vivo), By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others), By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others), By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Non-Clinical Trials Market is forecast to grow from USD 11.23 Billion in 2025 to USD 16.65 Billion by 2031, achieving a 6.78% CAGR, as these essential in vitro and in vivo studies evaluate drug candidate safety, toxicity, and efficacy before human trials. This market expansion is primarily driven by escalating global investment in drug discovery pipelines, prompted by the rising prevalence of chronic and complex diseases, with the European pharmaceutical industry alone investing approximately €55 billion in R&D in 2024. However, the market faces a significant challenge from ethical and regulatory pressures surrounding animal testing, compelling a shift towards alternative methods like computer modeling or organ-on-a-chip technologies; while ethically progressive, the complex validation processes and high costs of integrating these non-animal alternatives into regulatory frameworks can cause operational delays and impede immediate market growth.
Market Driver
The primary catalyst for the Global Non-Clinical Trials Market is the substantial surge in pharmaceutical and biotechnology R&D expenditure, as increased investment directly translates to a higher volume of drug candidates requiring rigorous safety assessments, evidenced by AstraZeneca's 24% rise in R&D expenses to $13.6 billion and the FDA's approval of 50 novel drugs in 2024, each necessitating extensive prior non-clinical testing. A second major driver is the growing trend of outsourcing non-clinical studies to Contract Research Organizations (CROs), which allows companies to leverage specialized external expertise, optimize costs, and focus internal resources on core discovery efforts, maintaining substantial revenue for service providers like Charles River Laboratories, which reported $1.00 billion in revenue for Q3 2025, while also accelerating development timelines and providing access to advanced testing technologies.
Market Challenge
A significant hurdle for the Global Non-Clinical Trials Market is the stringent regulatory landscape, largely fueled by ethical concerns regarding animal welfare, which compels pharmaceutical companies to reduce their reliance on established in vivo testing models. This mandated transition creates a bottleneck due to the resource-intensive and prolonged validation processes for non-animal alternatives, disrupting workflows and leading to a contraction in traditional testing volumes that complicates safety data generation and slows overall drug development timelines. This tightening is evidenced by the UK Home Office's report of a decrease in scientific procedures involving living animals to approximately 2.64 million in Great Britain in 2024, marking the lowest level since 2001; however, the lack of universal regulatory acceptance and costly customization for alternative methodologies extend development timelines and increase operational expenditures, directly impeding efficient market scaling.
Market Trends
The Integration of Artificial Intelligence (AI) for predictive toxicology and safety assessment is fundamentally reshaping non-clinical workflows by enabling pharmaceutical companies to deploy machine learning algorithms for early identification of potential toxicity risks before physical testing, thus accelerating candidate selection and enhancing safety profile precision, exemplified by Sanofi's 2024 strategic partnership with Formation Bio and OpenAI to develop AI-powered software for drug development. Concurrently, the Expansion of Specialized Safety Testing for Biologics and Advanced Therapies is gaining momentum as the pipeline shifts towards complex cell and gene therapies requiring bespoke protocols for risks like immunogenicity and tumorigenicity, creating demand for highly specialized toxicology services. This trend is supported by substantial capital inflows, with the cell and gene therapy sector receiving $10.9 billion in investments in the first half of 2024, driven by late-stage clinical progress, ensuring funding for these rigorous non-clinical studies.
Key Market Players
* Thermo Fisher Scientific Inc.
* Charles River Laboratories International, Inc.
* Covance Inc.
* IQVIA Holdings, Inc.
* WuXi AppTec Co., Ltd.
* Eurofins Scientific
* Evotec SE
* Envigo RMS, LLC
* Absorption Systems, LLC
Report Scope
In this report, the Global Non-Clinical Trials Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Non-Clinical Trials Market, By Study Type
* Pharmacodynamics (PD) studies
* Pharmacokinetics (PK) studies
* Toxicology studies
# Non-Clinical Trials Market, By Test
* In silico
* In vitro
* In vivo
# Non-Clinical Trials Market, By Therapeutic Area
* Oncology
* Cardiovascular
* Neurology
* Immunology
* Others
# Non-Clinical Trials Market, By End User
* Pharmaceutical and Biotechnology Companies
* Contract Research Organizations (CROs)
* Academic and Government Research Institutes
* Others
# Non-Clinical Trials Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Non-Clinical Trials Market.
Available Customizations:
Global Non-Clinical Trials Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Non-Clinical Trials Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Study Type (Pharmacodynamics (PD) studies, Pharmacokinetics (PK) studies, Toxicology studies)
5.2.2. By Test (In silico, In vitro, In vivo)
5.2.3. By Therapeutic Area (Oncology, Cardiovascular, Neurology, Immunology, Others)
5.2.4. By End User (Pharmaceutical and Biotechnology Companies, Contract Research Organizations (CROs), Academic and Government Research Institutes, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Non-Clinical Trials Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Study Type
6.2.2. By Test
6.2.3. By Therapeutic Area
6.2.4. By End User
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Non-Clinical Trials Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Study Type
6.3.1.2.2. By Test
6.3.1.2.3. By Therapeutic Area
6.3.1.2.4. By End User
6.3.2. Canada Non-Clinical Trials Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Study Type
6.3.2.2.2. By Test
6.3.2.2.3. By Therapeutic Area
6.3.2.2.4. By End User
6.3.3. Mexico Non-Clinical Trials Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Study Type
6.3.3.2.2. By Test
6.3.3.2.3. By Therapeutic Area
6.3.3.2.4. By End User
7. Europe Non-Clinical Trials Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Study Type
7.2.2. By Test
7.2.3. By Therapeutic Area
7.2.4. By End User
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Non-Clinical Trials Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Study Type
7.3.1.2.2. By Test
7.3.1.2.3. By Therapeutic Area
7.3.1.2.4. By End User
7.3.2. France Non-Clinical Trials Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Study Type
7.3.2.2.2. By Test
7.3.2.2.3. By Therapeutic Area
7.3.2.2.4. By End User
7.3.3. United Kingdom Non-Clinical Trials Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Study Type
7.3.3.2.2. By Test
7.3.3.2.3. By Therapeutic Area
7.3.3.2.4. By End User
7.3.4. Italy Non-Clinical Trials Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Study Type
7.3.4.2.2. By Test
7.3.4.2.3. By Therapeutic Area
7.3.4.2.4. By End User
7.3.5. Spain Non-Clinical Trials Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Study Type
7.3.5.2.2. By Test
7.3.5.2.3. By Therapeutic Area
7.3.5.2.4. By End User
8. Asia Pacific Non-Clinical Trials Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Study Type
8.2.2. By Test
8.2.3. By Therapeutic Area
8.2.4. By End User
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Non-Clinical Trials Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Study Type
8.3.1.2.2. By Test
8.3.1.2.3. By Therapeutic Area
8.3.1.2.4. By End User
8.3.2. India Non-Clinical Trials Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Study Type
8.3.2.2.2. By Test
8.3.2.2.3. By Therapeutic Area
8.3.2.2.4. By End User
8.3.3. Japan Non-Clinical Trials Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Study Type
8.3.3.2.2. By Test
8.3.3.2.3. By Therapeutic Area
8.3.3.2.4. By End User
8.3.4. South Korea Non-Clinical Trials Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Study Type
8.3.4.2.2. By Test
8.3.4.2.3. By Therapeutic Area
8.3.4.2.4. By End User
8.3.5. Australia Non-Clinical Trials Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Study Type
8.3.5.2.2. By Test
8.3.5.2.3. By Therapeutic Area
8.3.5.2.4. By End User
9. Middle East & Africa Non-Clinical Trials Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Study Type
9.2.2. By Test
9.2.3. By Therapeutic Area
9.2.4. By End User
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Non-Clinical Trials Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Study Type
9.3.1.2.2. By Test
9.3.1.2.3. By Therapeutic Area
9.3.1.2.4. By End User
9.3.2. UAE Non-Clinical Trials Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Study Type
9.3.2.2.2. By Test
9.3.2.2.3. By Therapeutic Area
9.3.2.2.4. By End User
9.3.3. South Africa Non-Clinical Trials Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Study Type
9.3.3.2.2. By Test
9.3.3.2.3. By Therapeutic Area
9.3.3.2.4. By End User
10. South America Non-Clinical Trials Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Study Type
10.2.2. By Test
10.2.3. By Therapeutic Area
10.2.4. By End User
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Non-Clinical Trials Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Study Type
10.3.1.2.2. By Test
10.3.1.2.3. By Therapeutic Area
10.3.1.2.4. By End User
10.3.2. Colombia Non-Clinical Trials Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Study Type
10.3.2.2.2. By Test
10.3.2.2.3. By Therapeutic Area
10.3.2.2.4. By End User
10.3.3. Argentina Non-Clinical Trials Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Study Type
10.3.3.2.2. By Test
10.3.3.2.3. By Therapeutic Area
10.3.3.2.4. By End User
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Non-Clinical Trials Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Thermo Fisher Scientific Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Charles River Laboratories International, Inc.
15.3. Covance Inc.
15.4. IQVIA Holdings, Inc.
15.5. WuXi AppTec Co., Ltd.
15.6. Eurofins Scientific
15.7. Evotec SE
15.8. Envigo RMS, LLC
15.9. Absorption Systems, LLC
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們